-
公开(公告)号：US20240360242A1
公开(公告)日：2024-10-31
申请号：US18620397
申请日：2024-03-28
Applicant: KisoJi Biotechnology Inc.
Inventor： Wenyang HOU , Shugang YAO , Luis DA CRUZ , David S. YOUNG
CPC classification number: C07K16/30 , A61P35/00 , A61K2039/505 , C07K2317/565 , C07K2317/567 , C07K2317/569
Abstract: The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.
-
公开(公告)号：US20240352150A2
公开(公告)日：2024-10-24
申请号：US18021568
申请日：2020-09-21
Applicant: NINGBO COMGEN BIOTECH CO., LTD.
Inventor： Miao WANG , Pengfei XU
CPC classification number: C07K16/36 , A61P9/10 , C12N15/63 , C07K2317/565 , C07K2317/569
Abstract: A nanobody or an antigen-binding fragment thereof against a specific region of a factor XII (FXII) is provided. The nanobody or the antigen-binding fragment thereof binds to FXII through a binding epitope for FXII to block the activation of FXII, and the binding epitope for FXII includes a conformational epitope. A neutralizing antibody for FXII screened by phage display is provided, and it has been found that the neutralizing antibody can treat thrombosis, myocardial ischemia-reperfusion injury (IRI), and vasculitis in mouse arterial thrombosis, rat extracorporeal membrane oxygenation (ECMO), mouse IRI, and vasculitis models.
-
公开(公告)号：US20240349732A1
公开(公告)日：2024-10-24
申请号：US18637092
申请日：2024-04-16
Applicant: IMPETUS AGRICULTURE, INC.
Inventor： Heba Mohamed Yassen ABDELGAFFAR , Constanze HAHNFELD , Juan Luis JURAT-FUENTES , Erik JONGEDIJK , JEFFREY M. STAUB , Stefan MELDAU
CPC classification number: A01N63/50 , A01P7/04 , C07K14/325 , C07K16/1278 , C07K16/18 , C07K16/28 , C07K2317/22 , C07K2317/31 , C07K2317/569 , C07K2317/92 , C07K2319/55
Abstract: Affinity constructs and affinity molecules to direct insecticidal toxins to insect specific structures of target insects are presented herein. The affinity constructs comprise of at least one affinity molecule that is capable of recognizing, or capable of binding to, or binding to, or being directed to, or being designed to bind to an insect-specific structure in and/or on a target insect, and at least one other affinity molecule capable of binding to, or binding to, or being directed to, or being designed to bind to an insecticidal protein (toxin) wherein the at least two affinity molecules are operably coupled. Presented herein are also methods of making and using these affinity constructs and affinity molecules.
-
公开(公告)号：US20240343811A1
公开(公告)日：2024-10-17
申请号：US18574812
申请日：2022-06-28
Applicant: SHANDONG SIMCERE BIOPHARMACUTICAL CO., LTD.
Inventor： Qiong Wang , Yayuan Fu , Cuiqing Yang , Zhuoxiao Cao , Renhong Tang , Jinsheng Ren
CPC classification number: C07K16/283 , G01N33/6854 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/569 , G01N2333/70535
Abstract: The present invention relates to a CD16 antibody and the use thereof. Specifically, disclosed are an antibody or an antigen-binding fragment specifically binding CD16, and an encoding nucleic acid, an expression vector and an expression cell thereof, a preparation method therefor, a pharmaceutical composition thereof, and the use thereof for treating diseases, such as the use thereof in the treatment of tumors. The CD16 antibody holds great significance for the development of a CD16 antibody therapeutic drug and a CD16 detection reagent.
-
公开(公告)号：US12116419B2
公开(公告)日：2024-10-15
申请号：US18157752
申请日：2023-01-20
Applicant: SYSMEX CORPORATION
Inventor： Shingo Maeta , Atsushi Fukunaga , Reema Bajaj
CPC classification number: C07K16/40 , C07K16/00 , C07K16/26 , C07K16/32 , G16B15/20 , G16B20/30 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/567 , C07K2317/569 , C07K2317/622 , C07K2317/92
Abstract: Disclosed is a method for improving affinity of an antibody for an antigen, comprising, in an unmodified antibody, improving affinity for an antigen as compared to the unmodified antibody, by changing 18th, 20th and 22nd amino acid residues of a light chain defined by Kabat method to charged amino acid residues.
-
公开(公告)号：US20240327543A1
公开(公告)日：2024-10-03
申请号：US18293515
申请日：2022-07-27
Applicant: SHENGHE (CHINA) BIOPHARMACEUTICAL CO., LTD.
Inventor： Chong ZHOU , Liusong YIN , Xiaoling JIANG
CPC classification number: C07K16/468 , A61P35/00 , C07K2317/31 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/569
Abstract: A multispecific antigen-binding protein including: (a) a first antigen-binding portion capable of recognizing the first antigen, where the first antigen is targeted to antigens associated with tumorigenesis or progression; (b) a second antigen-binding portion, where the second antigen-binding portion is an innate immune cell agonist; and (c) a third antigen-binding portion capable of recognizing the third antigen, where the third antigen regulates tumor microenvironment by regulating normal and abnormal angiogenesis. The embodiments further provide a pharmaceutical composition including the multispecific antigen-binding protein and a pharmaceutically acceptable carrier, and use of the multispecific antigen-binding protein and the pharmaceutical composition in the preparation of a drug for the treatment of cancer.
-
公开(公告)号：US20240327534A1
公开(公告)日：2024-10-03
申请号：US18583058
申请日：2024-02-21
Applicant: Harpoon Therapeutics, Inc.
Inventor： Holger WESCHE , Bryan D. LEMON , Richard J. AUSTIN
CPC classification number: C07K16/2878 , A61K47/6849 , A61P35/00 , A61P35/02 , A61P35/04 , C07K16/18 , C07K16/2809 , A61K2039/505 , C07K2317/21 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/569 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/92 , C07K2317/94
Abstract: Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.
-
公开(公告)号：US12098197B2
公开(公告)日：2024-09-24
申请号：US17698823
申请日：2022-03-18
Applicant: Sorriso Pharmaceuticals, Inc.
Inventor： Scott Crowe , Tim Carlton , Marion Cubitt , Kevin Roberts , Luana Maggiore , Mike West , Keith Ray
CPC classification number: C07K16/248 , A61K9/0053 , A61P29/00 , C07K16/2866 , A61K2039/505 , A61K2039/542 , C07K2317/22 , C07K2317/33 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
-
公开(公告)号：US20240309101A1
公开(公告)日：2024-09-19
申请号：US18470875
申请日：2023-09-20
Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
Inventor： Anne Goubier , Beatriz Goyenechea Corzo , Josephine Salimu , Kevin Moulder , Pascal Merchiers , Mark Brown , Sergio Quezada , James Geoghegan , Bianka Prinz
IPC: C07K16/28 , A61K39/00 , A61K39/395 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C12N15/85
CPC classification number: C07K16/2866 , A61K39/39533 , A61K39/39541 , A61K39/39558 , A61K39/39566 , A61K45/06 , A61P35/00 , A61P35/02 , C07K14/05 , C07K14/55 , C07K16/2818 , C07K16/2827 , C12N15/85 , A61K2039/505 , A61K2039/507 , C07K2317/20 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569 , C07K2317/60 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/74 , C07K2317/76 , C07K2317/92 , C12N2015/8518
Abstract: The present disclosure provides antibody sequences found in antibodies that bind to human CD25. In particular, the present disclosure provides sequences of anti-human CD25 antibodies, which do not block the binding of CD25 to IL-2 or IL-2 signalling. Antibodies and antigen-binding portions thereof including such sequences can be used in pharmaceutical composition and methods of treatment, in particular for treating cancer.
-
公开(公告)号：US20240309093A1
公开(公告)日：2024-09-19
申请号：US18263480
申请日：2022-01-28
Inventor： Guoqing CAO , Liyuan ZHU , Junwei SHI
CPC classification number: C07K16/2818 , G01N33/6854 , A61K2039/505 , C07K2317/21 , C07K2317/22 , C07K2317/24 , C07K2317/33 , C07K2317/565 , C07K2317/569 , C07K2317/76 , C07K2317/92
Abstract: An antigen binding protein and the use thereof. The antigen binding protein can compete with pembrolizumab for binding to the same or overlapping PD-1 epitope. The antigen binding protein can effectively inhibit the binding of human PD-L1 to human PD-1 with an EC50 of approximately 2 μg/mL or less.
